#688192
LightNews LightNews
stage.natalie.mu
バレエダンサーと俳優が織りなす「SWAN」開幕、小林香「新しい舞台表現にたどり着けた」（舞台写真10枚 / コメントあり）
https://natalie.mu/stage/news/688192?utm_source=bluesky&utm_medium=social
バレエダンサーと俳優が織りなす「SWAN」開幕、小林香「新しい舞台表現にたどり着けた」（舞台写真10枚 / コメントあり） - ステージナタリー
「SWAN－Ballet cross Reading－」が昨日9月4日に東京・新国立劇場 中劇場で開幕し、ゲネプロの舞台写真が公開された。併せて、脚本・演出を手がける小林香、バレエ監修・振付を担う福田圭吾、リーディングキャストの井桁弘恵、村川絵...
natalie.mu
September 5, 2026 at 5:00 AM
ke0opr.bsky.social
ICAO: #ADFFF4

Flt: #MAFIA1 #688192 #T38
Time: 2026-07-22 16:29:38 CDT
Min Alt: 25975 ft
Min Dist: 40.5 nm (111deg ESE)
Squawk: #2473
#adsb #planefence by kx1t sdr-e adsbexchange flightaware faa
July 22, 2026 at 9:46 PM
ke0opr.bsky.social
ICAO: #ADFFF4

Flt: #COOL11 #688192 #T38
Time: 2026-07-19 08:52:39 CDT
Min Alt: 2675 ft
Min Dist: 12.2 nm (140deg SE)

#adsb #planefence by kx1t sdr-e adsbexchange flightaware faa
July 19, 2026 at 2:09 PM
ke0opr.bsky.social
ICAO: #ADFFF4

Flt: #COOL11 #688192 #T38
Time: 2026-07-17 19:13:56 CDT
Min Alt: 2850 ft
Min Dist: 8.7 nm (130deg SE)

#adsb #planefence by kx1t sdr-e adsbexchange flightaware faa
July 18, 2026 at 12:21 AM
ke0opr.bsky.social
ICAO: #ADFFF4

Flt: #COOL11 #688192 #T38
Time: 2026-07-13 13:14:08 CDT
Min Alt: 16300 ft
Min Dist: 25.9 nm (110deg ESE)

#adsb #planefence by kx1t sdr-e adsbexchange flightaware faa
July 13, 2026 at 6:29 PM
ke0opr.bsky.social
ICAO: #ADFFF4

Flt: #COOL11 #688192 #T38
Time: 2026-07-09 16:16:56 CDT
Min Alt: 2325 ft
Min Dist: 10.37 nm (127deg SE)
Squawk: #4010
#adsb #planefence by kx1t sdr-e adsbexchange flightaware faa
July 9, 2026 at 9:25 PM
playing-games.bsky.social
Homdgcat経由の最後の2つのChrysos相続人の名前/タイトル

https://www.playing-games.com/688192/

Homdgcat経由の最後の2つのChrysos相続人の名前/タイトル by raadrules
Homdgcat経由の最後の2つのChrysos相続人の名前/タイトル - Playing Games
Homdgcat経由の最後の2つのChrysos相続人の名前/タイトル
www.playing-games.com
June 19, 2025 at 7:15 PM
babygoldie.bsky.social
[1/3] 2026-04-22 07:55:14 - [Dizhe Medicine: A number of research results in the field of lung cancer were selected to be reported at the 2026 American Society of Clinical Oncology (ASCO) Congress] Dizhe Medicine (688192) announced on the morning of April 22 that the company will be
April 22, 2026 at 12:10 AM
laotiantimes.com.web.brid.gy
Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKI In treatment-naïve patients with advanced NSCLC without driver mutations, Golidocitinib, a JAK-only inhibitor, in combination with anti-PD-1 antibody enhanced anti-tumor response. SHANGHAI, May 31, 2026 /PRNewswire/ — Dizal (SSE:688192), a […]
laotiantimes.com
May 31, 2026 at 8:27 AM
laotiantimes.com.web.brid.gy
Dizal’s ZEGFROVY® (Sunvozertinib) New Drug Application Accepted and Granted Priority Review by China National Medical Products Administration for First-Line Treatment of EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer
SHANGHAI, May 27, 2026 /PRNewswire/ — Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of oncology and hematological diseases, announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted and granted priority review to the New Drug Application (NDA) for ZEGFROVY® (sunvozertinib) for […]
laotiantimes.com
May 28, 2026 at 12:25 AM
laotiantimes.com.web.brid.gy
Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025
SHANGHAI, Dec. 9, 2025 /PRNewswire/ — Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, announced new data from its hematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting. Highlights include golidocitinib, a Janus kinase 1 (JAK1) only inhibitor, in T-cell lymphoma, and birelentinib, a non-covalent LYN/BTK […]
laotiantimes.com
December 9, 2025 at 11:51 AM
honkai-star-rail.bsky.social
Homdgcat経由の最後の2つのChrysos相続人の名前/タイトル

https://www.playing-games.com/688192/

Homdgcat経由の最後の2つのChrysos相続人の名前/タイトル by raadrules
Homdgcat経由の最後の2つのChrysos相続人の名前/タイトル - Playing Games
Homdgcat経由の最後の2つのChrysos相続人の名前/タイトル
www.playing-games.com
June 19, 2025 at 7:00 PM
overneworleans.possumsin.space
#PlaneAlert ICAO: #ADFF88 Tail: #688192 Flt: #BURNER1
Owner: #USAF
Aircraft: #Northrop T-38C Talon
2026-05-04 16:22:37 CDT
#T38 #Mil #TrainingWheels #BicycleMadeForTwo #MiG28 USAF
- wiki - adsbexchange
May 4, 2026 at 9:24 PM
overneworleans.possumsin.space
#PlaneAlert ICAO: #ADFF88 Tail: #688192 Flt: #SNIPER1
Owner: #USAF
Aircraft: #Northrop T-38C Talon
2026-04-10 09:47:25 CDT
#T38 #Mil #TrainingWheels #BicycleMadeForTwo #MiG28 USAF
- wiki - adsbexchange
April 10, 2026 at 2:47 PM
overneworleans.possumsin.space
#PlaneAlert ICAO: #ADFF88 Tail: #688192 Flt: #FADE1
Owner: #USAF
Aircraft: #Northrop T-38C Talon
2026-03-17 13:54:32 CDT
#T38 #Mil #TrainingWheels #BicycleMadeForTwo #MiG28 USAF
- wiki - adsbexchange
March 17, 2026 at 6:55 PM
overneworleans.possumsin.space
#PlaneAlert ICAO: #ADFF88 Tail: #688192 Flt: #SNIPER1
Owner: #USAF
Aircraft: #Northrop T-38C Talon
2026-02-27 13:20:20 CST
#T38 #Mil #TrainingWheels #BicycleMadeForTwo #MiG28 USAF
- wiki - adsbexchange
February 27, 2026 at 7:21 PM
planesovermemphis.bsky.social
#PlaneAlert ICAO: #ADFF88

Flt: #68-8146 #688192 #T38
Time: 2026-04-08 09:54:05 CDT
Min Alt: 20875 ft

#adsb #planefence #planealert by kx1t sdr-e adsbexchange flightaware faa
April 8, 2026 at 2:55 PM
l2plabs.bsky.social
Dizal's ZEGFROVY® (Sunvozertinib) New Drug Application Accepted and Granted Priority Review by China National Medical Products Administration for First-Line Treatment of EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer
SHANGHAI, May 27, 2026 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of oncology and hematological diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration...
dlvr.it
May 27, 2026 at 10:45 AM
l2plabs.bsky.social
Dizal's ZEGFROVY® (Sunvozertinib) Shows Profound Antitumor Activity as First-Line Treatment in Advanced NSCLC Patients with PACC or Other Uncommon Mutations at ELCC 2026
First-line ZEGFROVY® monotherapy demonstrated an objective response rate (ORR) of 81.3% in patients with advanced NSCLC harboring EGFR PACC or other uncommon mutations, with a manageable safety profile SHANGHAI, March 27, 2026 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical...
dlvr.it
March 27, 2026 at 12:44 PM